Novo Nordisk begins cutting 9,000 jobs worldwide

Novo Nordisk has laid off dozens of workers at its Clayton, North Carolina plant, the largest US manufacturing site for its obesity and diabetes drugs, according to a Reuters review of LinkedIn posts published October 7 ^[1]. The cuts are part of a global restructuring announced September 10 that will eliminate about 9,000 jobs ^[1][2].

Reuters analyzed 73 posts and profiles and found the cuts hit manufacturing roles, from quality control staff to production line technicians, at the Clayton site and other Novo facilities in North Carolina ^[1]. Of those, 47 people posted directly that they had been laid off or were looking for work ^[1]. The layoffs also affected project coordinators and an HR assistant ^[1]. Reuters said it could not determine the exact number of jobs cut in Clayton or the specific reason ^[1]. A Novo spokesperson declined to give details beyond the September announcement, saying, "This process takes time and our highest priority is to support our employees" ^[1].

What the restructuring involves

Novo Nordisk said in September it would cut roughly 9,000 positions out of 78,400 employees worldwide, including 5,000 in Denmark ^[2]. The company framed the move as a way to simplify its organization, speed up decision-making and shift resources toward diabetes and obesity ^[2]. CEO Mike Doustdar said in the announcement that "our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven" ^[2].

The financial targets: about $1.25 billion in annual savings by 2026, to be reinvested in commercial work, R&D and manufacturing scale-up ^[2]. Against that, Novo expects roughly $1.26 billion in net one-off costs, including impairments, with about $1.41 billion booked in the third quarter of 2025 and $157 million in offsetting savings in the fourth quarter ^[2]. The company cut its 2025 operating profit growth forecast at constant exchange rates to 4%–10%, down from 10%–16% ^[2]. Novo had already imposed a hiring freeze for non-business-critical roles in August ^[2].

The Clayton plant matters for supply. It makes semaglutide, the active ingredient in Wegovy and Ozempic, and handles filling, finishing and packaging of the injections ^[1]. Reuters reported it will also play a key role in producing the pill version of Wegovy once that becomes available ^[1]. Doustdar recently promoted an ongoing $4.1 billion expansion at the site, which employed about 2,500 people in 2024 and was expected to add 1,000 more ^[1]. So the company is expanding capacity there while trimming some frontline roles at the same time ^[1].

The backdrop is competition. Novo became Europe's most valuable listed company on weight-loss drug demand before its share price slid as sales growth slowed ^[1]. It is now trying to claw back ground against Eli Lilly, whose tirzepatide products Zepbound and Mounjaro compete directly with Wegovy and Ozempic ^[1][2]. Earlier Novo cuts in the US hit its obesity education team ^[1].

Why it matters for patients

For people filling semaglutide prescriptions in the US, the direct question is whether supply changes. The sources do not say the layoffs have affected output at Clayton, and Novo has not linked the cuts to production volumes ^[1]. What the reporting does show is that the cost-cutting reached frontline manufacturing and quality control roles at the plant that makes the drug substance and packages the pens ^[1]. Whether that has any effect on availability is not yet known from these sources.

The cuts to the US obesity education team are a more visible change for patients and clinicians, since that team's work involves information and outreach around obesity treatment ^[1]. Novo has not detailed what replaces it.

There is also a broader signal. A company reinvesting savings into "commercial execution, R&D, and manufacturing scale-up" in diabetes and obesity is a company betting harder on this drug class ^[2]. That competitive pressure between Novo and Lilly has already shaped pricing and access moves in the US market, though none of that is detailed in these sources.

What happens next

• September 10, 2025: Novo announced the 9,000-job reduction and lowered its 2025 profit outlook ^[2].
• Third quarter 2025: about $1.41 billion in one-off restructuring costs recorded ^[2].
• Fourth quarter 2025: roughly $157 million in offsetting savings expected ^[2].
• By end of 2026: the full $1.25 billion in annual savings is targeted ^[2].

Novo has provided little public detail about where the remaining cuts will land ^[1].